This post was originally published on Medscape
You will shortly be re-directed to the publisher's website
Researchers have identified a range of genetic alterations that may lead to resistance to KRAS G12C inhibitors in patients with KRAS G12C–mutant colorectal and pancreatic cancers.
Medscape Medical News